Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 50,750

Document Document Title
WO/2021/089559A1
The present disclosure relates to a method of treating kidney injury, by administering an anti-IL- 33 therapeutic agent which inhibits both ST2 signaling and RAGE signaling.  
WO/2021/088495A1
Provided are a crystal form I of a curcumin derivative (C66), a preparation method therefor and an application thereof, which relate to the field of the medical and chemical industry. The crystal form I contains characteristic peaks meas...  
WO/2021/089692A1
A compound for use in the treatment of nephrotic syndrome in a subject in need thereof, wherein the compound is an inhibitor of binding between a target protein and keratin 8.  
WO/2021/089300A1
The present invention relates to compounds 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3- isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00, TT001 and/or TT002), or a pharmaceutical composition comprising said TT00, TT001 and/or TT0...  
WO/2021/084483A1
The principles and embodiments of the present disclosure relate to methods of increasing survival of a patient having type 1 hepatorenal syndrome (HRS-1) and low mean arterial pressure (MAP). The methods may include identifying a patient...  
WO/2021/085540A1
Provided are: a novel fluorine-containing pyrimidine compound with substituents at the 4-position, the 5-position, and the 6-position and a furan ring structure as a substituent at the 2-position; and a manufacturing method by which the ...  
WO/2021/086874A1
The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof. (I)  
WO/2021/086120A1
The present invention relates to a composition, comprising a Salvia miltiorrhiza Bunge extract as an active ingredient, for treatment or prevention of benign prostatic hyperplasia or alopecia. The Salvia miltiorrhiza Bunge extract compri...  
WO/2021/085639A1
The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for ameliorat...  
WO/2021/085295A1
The present invention addresses the problem of clarifying the immune response mechanism of IL-17-producing cells, said immune response mechanism inducing pathological conditions such as psoriasis, to thereby provide an immune response su...  
WO/2021/083372A1
A solid composition containing angiotensin II, a preparation method and use method therefor and a use thereof. The composition comprises angiotensin II and an auxiliary additive, wherein the auxiliary additive comprises sulfobutyl beta c...  
WO/2021/086967A1
The present invention relates to a method of treating subjects with diabetic nephropathy by administering certain dosages of Compound I, a stimulator of soluble guanylate cyclase (sGC), either alone or in combination therapy.  
WO/2021/081141A1
Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthas...  
WO/2021/078359A1
Chronic Kidney Disease (CKD) is a major burden of public health affecting millions of people around the world. Even though many aspects of the complex mechanisms orchestrating progression of renal disease have been identified, so far the...  
WO/2021/079303A1
A pharmaceutical sterile composition consisting of hyaluronic acid sodium salt and Hyaffl lp50 and related use in the intravesical treatment of interstitial cystitis or Bladder Pain Syndrome (IC/BPS), of acute cystitis following bacteria...  
WO/2021/079536A1
This composition for lysis of Staphylococcus aureus or this composition for prevention or therapy of diseases caused by Staphylococcus aureus contains as active ingredients: at least one bacteriophage selected from the group consisting o...  
WO/2021/081006A1
There are provided, in some embodiments, therapeutic compositions and methods for preventing, inhibiting, reducing, or treating cardiac ischemic reperfusion injury. The therapeutic composition can comprise a plurality of microRNA (miR) a...  
WO/2021/079869A1
The present invention addresses the problem of providing a uremic toxin reducing agent, a total cholesterol reducing agent and a neutral fat reducing agent. The abovementioned problem is solved by a uremic toxin reducing agent, a total...  
WO/2021/079986A1
A composition for lysing Staphylococcus aureus or a composition for preventing or treating a disease caused by Staphylococcus aureus, said composition comprising, as active ingredients, at least one bacteriophage selected from the group ...  
WO/2021/079435A1
This composition is for lysing Staphylococcus aureus or treating or preventing diseases caused by Staphylococcus aureus, and contains, as active ingredients, at least one bacteriophage selected from the group consisting of the bacterioph...  
WO/2021/078835A1
The present invention relates to pharmaceutical compositions comprising 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu lfonyl)acetamide (selexipag, NS-304, ACT-293987) which are suitable for oral administratio...  
WO/2021/077994A1
Disclosed are a new crystal form of compound I and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and the use of the crystal form in the preparation of hypoxia-inducible factor-prolyl hydroxylase...  
WO/2021/079984A1
The present invention provides a novel compound having an excellent β-lactamase inhibitory effect. The present invention provides: a compound which has an excellent β-lactamase inhibitory effect, and is represented by formula (1a), (1b...  
WO/2021/073249A1
Disclosed is the use of β-nicotinamide mononucleotide in the preparation of a drug for treating and/or preventing sepsis-induced organ damage. The new use of β-nicotinamide mononucleotide has a therapeutic effect and a preventive effec...  
WO/2021/074598A1
The present invention relates to a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and a tetracycline antibiotic or a pharmaceutically acceptable derivative or prodrug thereof, for use in treating a ...  
WO/2021/076076A1
The invention relates to a production method of a medical solution comprising hyaluronic acid or sodium salt (sodium hyaluronate) and polyethylene glycol developed for use in the treatment of cystitis disease, wherein it discloses a prod...  
WO/2021/075585A1
The present invention provides a therapeutic agent, etc., for renal dysfunction. The present invention pertains to a therapeutic agent, a therapeutic pharmaceutical composition, etc., for renal dysfunction (such as polycystic kidney dise...  
WO/2021/074198A1
This invention relates to tetrazoles and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammato...  
WO/2021/037289A3
Disclosed are a recombinant fusion polypeptide, a preparation method therefor, and a use thereof. A recombinant fusion polypeptide, said recombinant fusion polypeptide being expressed as the following general formula: X-linker1-Y, Y-link...  
WO/2021/037291A3
Provided is a fusion polypeptide having multifunctional activities, the amino acid sequence of the fusion polypeptide being: Pro-Arg-Cys-X-Y-Gly-Glu-Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala- Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp...  
WO/2021/075536A1
The present disclosure provides a therapy for diabetes that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases a...  
WO/2021/071451A1
The invention, in order to be used in the healthcare industry provided by biotechnology-nanotechnology, a targeted dual cytotoxic effective nano-metallo system for the treatment of non-metastasized castration-resistant prostate cancer, c...  
WO/2021/037290A3
Provided is a fusion polypeptide, containing domains N-Acetyl-Ser-Asp-Lys-Pro, Ser-Asp-Lys-Pro, Thr-Ser-Leu-Asp-Ala-Ser-Ile-Ile-Trp-Ala-Met-Met-Gln-Asn and Leu-Ser-Lys-Leu, or any mutated amino acids in the described domains, the domains...  
WO/2021/068957A1
Provided herein is Compound I or a pharmaceutically acceptable salt thereof for use in the prevention and/or treatment of a kidney condition or disease in a subject exposed to a nephrotoxin capable of inducing said kidney condition or di...  
WO/2021/071941A1
The present technology relates to methods comprising the administration of methotrexate and glucarpidase to treat central nervous system lymphoma in a subject in need thereof. Kits for use in practicing the methods are also provided.  
WO/2021/069944A1
The present invention relates to a pharmaceutical composition comprising mirabegron and to a process for manufacturing the same. The pharmaceutical composition includes one or a addition second polyethylene oxide as a release-controlling...  
WO/2021/065027A1
Provided is a dysuria-alleviating agent useful for treating or alleviating (or mitigating) dysuria regardless of the presence or degree of prostatomegaly. The dysuria-alleviating agent includes, as an active ingredient, a 2-oxapregnane...  
WO/2021/063945A1
The invention relates to a combined therapy including an inhibitor of interleukin-17 (IL-17) activity for use in combination with a vitamin D receptor agonist in the prevention and/or treatment of diseases or conditions known as autoimmu...  
WO/2021/067946A1
Disclosed are compounds having structural formulas (I)-(XI), and related pharmaceutical compositions. Also disclosed are methods of selecting and treating human subjects suffering from a kidney disease, using the compounds of formulas (I...  
WO/2021/067439A1
The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domain...  
WO/2021/066175A1
As a system enabling effective delivery of a medicinal active ingredient to the submucosa of bladder, provided is a transmucosal delivery system that comprises a complex of a hydrophobic compound containing the medicinal active ingredien...  
WO/2021/064575A1
The invention provides, FXR agonists for the treatment of a condition or a disease associated with mitochondrial dysfunction, e.g. a mitochondrial disease, in a subject in need thereof.  
WO/2021/066549A1
The present invention relates to Lactobacillus acidophilus KBL409 strain and use thereof. The Lactobacillus acidophilus KBL409 strain (accession number KCTC 13518BP) according to the present invention reduces kidney inflammation and the ...  
WO/2021/066608A1
The present invention relates to a compound for inducing the expression of the anti-aging gene klotho and a production method therefor. The compound represented by chemical formula 1, according to the present invention, has an excellent ...  
WO/2021/067943A1
Disclosed herein are Piezo 1 agonists. Also disclosed herein are methods of stimulating tissue anabolism in a subject comprising administering an effective amount of a Piezo 1 agonist and methods for chemically mimicking mechanical stimu...  
WO/2021/065686A1
Provided are a nucleic acid with improved ability to inhibit the expression of the MEX3B gene with low occurrence of cytotoxicity side effects, an MEX3B gene expression inhibiting agent that includes the nucleic acid, a method for inhibi...  
WO/2021/056946A1
Provided is an application of an anti-LCN2 antibody in preparation of a drug for treating lupus nephritis.  
WO/2021/060264A1
Provided is a composition that improves renal function. This composition for improving renal function contains glycine and tryptophan, wherein the content ratio by mass of glycine to tryptophan is more than 10 and less than 60.  
WO/2021/057782A1
Disclosed are a TAM family kinase /and Ron kinase inhibitor compound as shown in general formula (I), a pharmaceutically acceptable salt, an ester, a stereoisomer and a tautomer thereof, a pharmaceutical composition and a pharmaceutical ...  
WO/2021/060281A1
The purpose of the present invention is to provide a novel compound which has a prostaglandin E2 (PGE2) receptor EP2/EP4 dual antagonizing effect and is useful as: a preventive or therapeutic agent for a disease selected from cancer, pai...  

Matches 1 - 50 out of 50,750